מיפג'ין

Country: Israel

Language: Hebrew

Source: Ministry of Health

Active ingredient:

MIFEPRISTONE

Available from:

A. LAPIDOT PHARMACEUTICALS, LTD

ATC code:

G03XB01

Pharmaceutical form:

טבליה

Composition:

MIFEPRISTONE 200 MG

Administration route:

פומי

Prescription type:

מרשם נדרש

Manufactured by:

EXELGYNE LABORATORIES, FRANCE

Therapeutic group:

MIFEPRISTONE

Therapeutic area:

MIFEPRISTONE

Therapeutic indications:

Medical alternative to uterine suction for termination of intra-utrerine Pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after Mifegyne intake. Under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

Authorization date:

2014-07-31